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Abstract
On March 19, 2008 a Symposium on Pathophysiology of Ageing and Age-Related diseases was held
in Palermo, Italy. Here, the lectures of M. Racchi on History and future perspectives of Alzheimer
Biomarkers and of G. Scapagnini on Cellular Stress Response and Brain Ageing are summarized.
Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease, which in
Western society mainly accounts for clinica dementia. AD prevention is an important goal of
ongoing research. Two objectives must be accomplished to make prevention feasible: i) individuals
at high risk of AD need to be identified before the earliest symptoms become evident, by which
time extensive neurodegeneration has already occurred and intervention to prevent the disease is
likely to be less successful and ii) safe and effective interventions need to be developed that lead to
a decrease in expression of this pathology. On the whole, data here reviewed strongly suggest that
the measurement of conformationally altered p53 in blood cells has a high ability to discriminate
AD cases from normal ageing, Parkinson's disease and other dementias. On the other hand,
available data on the involvement of curcumin in restoring cellular homeostasis and rebalancing
redox equilibrium, suggest that curcumin might be a useful adjunct in the treatment of
neurodegenerative illnesses characterized by inflammation, such as AD.
Background
On March 19, 2008 a Symposium on Pathophysiology of
Ageing and Age-Related diseases was held in Palermo,
Italy. Here, the lectures of M. Racchi on History and future
perspectives of Alzheimer Biomarkers and of G.
Scapagnini on Cellular Stress Response and Brain Ageing
are summarized.
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder affecting aged people; AD prevalence is
approximately 1% between 65 and 69 years and is higher
than 50% in individuals above 95 years. It is characterized
by irreversible cognitive and physical deterioration. With
increasing life expectancy across the world, dementia is a
rapidly growing socioeconomic and medical problem.
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The confirmatory diagnosis of AD is based on the recogni-
tion and quantification of senile plaques and neurofibril-
lary tangles, which are the hallmarks of the disease [1].
AD prevention is an important goal of ongoing research.
Two objectives must be accomplished to make prevention
feasible: i) individuals at high risk of AD need to be iden-
tified before the earliest symptoms become evident, by
which time extensive neurodegeneration has already
occurred and intervention to prevent the disease is likely
to be less successful and ii) safe and effective interventions
need to be developed that either reduce or slow the accu-
mulation of AD neuropathology or lead to a decrease in
clinical expression of this pathology [2].
p53 as a putative peripheral marker for AD
The treatment of AD remains a major challenge because of
an incomplete understanding of the events that lead to the
selective neurodegeneration typical of Alzheimer's brains.
Nowadays the attention is focused on one side on the
study of the β-amyloid (Aβ) precursor protein (APP)
metabolism's pharmacological modulation, and on the
other one to develop disease-modifying or -arresting com-
pounds. The first purpose is that to reduce the develop-
ment of Aβ in the hope of reducing the formation of a
potentially neurotoxic peptide whereas examples of the
second concern the use either of monoclonal antibodies
direct to inflammatory mediators or of β-sheet breakers
[2-6].
In view of existing and emerging therapeutic compounds,
the focus has increasingly shifted to accurate detection of
the earliest phase of illness and, to date, there is an
increasing interest to develop techniques allowing an
accurate detection of the earliest stages of the disease.
Candidate biochemical markers for AD should be mole-
cules representing some of the cerebral pathogenetic proc-
esses typical of AD or representing altered metabolic or
cellular processes as shown by several studies performed
either on brain or on peripheral tissues from affected
patients. A wide variety of different proteins such as
inflammatory markers, markers of oxidative stress, apoli-
poproteins, and markers of neuronal degeneration in
blood and cerebrospinal fluid (CSF) have been examined
[7,8]. Most of these studies have, however, yielded con-
flicting results. The cerebrospinal fluid has been the focus
of research for diagnostic markers in AD pathology due to
its direct contact with the extracellular space of the brain
[7]. The more encouraging results come from the studies
on the measurement of different isoforms of Aβ in CSF,
particularly Aβ 1–42 [9], due to its role in the early patho-
genesis of AD. Most studies showed that Aβ 1–42 concen-
trations are lower in the CSF of AD [7,8]. Unfortunately,
plasma Aβ 1–40 and Aβ 1–42 did not correlate with the
disease. In fact the results from these studies are often con-
tradictory [10].
The biological markers can be classified as primary (spe-
cific), such as Aβ, or secondary to the disease, or they can
simply be epiphenomenal in nature. In search of second-
ary markers, Uberti et al. demonstrated an intriguing cor-
relation between p53 and AD by using cell lines derived
from these patients [11]. Fibroblasts of sporadic AD
patients represent an important starting point in the
research for novel biomarkers because of their various
abnormalities in metabolic and biochemical processes,
which reflect some of the events in the AD brain. They
described and demonstrated an abnormal response of AD
fibroblasts to an acute oxidative injury; in particular,
fibroblasts from AD patients were found to be less vulner-
able to the oxidative injury induced by H2O2 in compari-
son with fibroblasts from non-AD subjects. On the basis
of immunoprecipitation studies with conformation-spe-
cific p53 antibodies, which discriminated folded vs.
unfolded p53 tertiary structure, they found that in fibrob-
lasts from AD patients a significant amount of total p53
assumes an unfolded tertiary structure in comparison
with fibroblasts from control elderly subjects. Sequence
analysis of the p53 gene allowed to exclude the possibility
that the mutant p53 found in AD fibroblasts was the result
of gene mutation. Thus, these data suggest that one of the
peripheral events associated to the disease is responsible
for generating such p53 isoform [11,12].
In the attempt of investigating on the mechanism of such
alteration, they assessed the contribution of APP meta-
bolic products to the change in p53 conformational state.
They found that the exposure to nanomolar concentra-
tions of beta-amyloid (Aβ) 1–40 peptide induced the
expression of an unfolded p53 protein isoform in fibrob-
lasts derived from non-AD subjects. These data suggest
that the tertiary structure of p53 and the sensitivity to p53-
dependent apoptosis are influenced by low concentra-
tions of soluble Aβ. On this basis, they hypothesised that
low amounts of soluble Aβ induce early pathological
changes at cellular level that may precede the amyloidog-
enic cascade. One of these changes is the induction of a
novel conformational state of p53 [11,13].
In addition and most importantly, Lanni et al. [14] were
able to develop a rapid, easy and quantitative flow cyto-
metric approach for the discrimination of conformational
mutant p53-bearing cells from AD patients compared to
non-AD controls, using small volumes of blood. Using
this technique, they processed 75 AD, 66 controls, 15 sub-
jects affected by another neuroinflammatory disease, Par-
kinson's disease and 3 subjects affected with other types of
dementia (2 vascular dementia; 1 progressive supranu-
clear palsy) and confirmed the previous findings: AD sub-
jects expressed higher levels of unfolded p53 in
comparison with controls and subjects with other neuro-
logical diseases. The levels of conformationally altered
p53, both in controls and AD patients, correlated with ageImmunity & Ageing 2008, 5:7 http://www.immunityageing.com/content/5/1/7
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but not with the lenght of illness or with the Mini Mental
State Examination value. Interestingly, the sensitivity and
specificity within different age intervals were more signif-
icant in subjects up to 70 years of age compared with the
corresponding values for individuals older than 70 years.
Within this specific age interval (≤ 70 years), the Authors
worked out a sensitivity of 90% to discriminate AD
patients from nondemented aged individuals at a specifi-
city value of 77%. A comparison of these sensitivity and
specificity values with those published in several studies,
which evaluated the diagnostic power of CSF markers for
AD (Total-tau, Phospho-tau and Abeta 1–42), reveal that
p53 measurement is more sensitive (90% compared to
respectively 81.4%, 81.3% and 85.9%), but less specific
(77% compared to respectively 91.5%, 91.2% and
88.5%) [7].
On the whole, these data strongly suggest that the meas-
urement of conformationally altered p53 in blood cells
has a high ability to discriminate AD cases from normal
ageing, Parkinson's disease and other dementias. In spite
of the fact that the method described in this study has a
lower specificity value compared to CSF biomarkers, its
high sensitivity in subjects up to 70 years and the non
invasive nature of the test, permit its proposal as an
adjunctive marker. Accordingly, p53 analysis may be used
in the clinical evaluation of mild cognitive impairment
cases or to improve a clinical diagnosis of AD, which
should be based on cumulative information derived from
clinical examination, brain neuroimageing techniques
and biochemical markers either from CSF or blood. In a
disease where therapeutic treatments are at most sympto-
matic, early treatment and therefore early prediction of
future pathology is particularly important. Whether this
different expression of conformationally altered p53 will
be suitable as an adjunctive diagnostic tool in early stage
AD in larger and independent populations of patients is
matter of further investigations.
On the other hand, p53 is a hot topic in AD research.
Interestingly, it has been hypothesised that oxidative
modification of p53 could be involved in the neuronal
loss observed in neurodegenerative conditions [15,16].
Cellular stress response
Oxidative stress has been implicated in a variety of patho-
physiological conditions, including neurodegenerative
disorders. Irrespective of the source and mechanisms that
lead to the generation of reactive oxygen species, mamma-
lian cells have developed highly regulated inducible
defensive systems, whose cytoprotective functions are
essential in terms of cell survival. When appropriately acti-
vated, each one of these systems has the possibility to
restore cellular homeostasis and rebalance redox equilib-
rium. Activation of antioxidant pathways is particularly
important for tissue with relatively weak endogenous
antioxidant defenses, such as the brain. Increasing evi-
dences, in fact, support the notion that reduction of cellu-
lar expression and activity of antioxidant proteins and
consequent augment of oxidative stress are fundamental
causes for aging processes and neurodegenerative diseases
[17]. Among the molecules belonging to stress protein
family, Heme oxygenase-1 (HO-1) has been the object of
intensive studies in the brain for its potential role in pro-
tecting neurons against cell death. HO enzymes provide
the first and rate-limiting step in heme degradation, to
give biliverdin, gaseous carbon monoxide and free iron.
All the byproducts of HO activity play a significant role in
physiological cell functions [18]. In the CNS, the HO sys-
tem has been reported to be very active [19,20] and its
modulation seems to play a crucial role in the pathogene-
sis of neurodegenerative disorders. Deregulation of the
HO system has been associated with the pathogenesis of
Alzheimer's disease, multiple sclerosis and brain aging
[21,22]. Many studies clearly demonstrate that activation
of HO-1 in neurons is strongly protective against oxida-
tive damage and cell death [23]. Thus, modulation of HO-
1 should represent a potential pharmaceutical strategy for
the treatment of neurodegenerative disorders. A number
of experimental and epidemiological studies have recently
supported the beneficial effects of some commonly used
natural products in preventing various pathologic condi-
tions ranging from cardiovascular diseases to cancer.
Spices and herbs often contain phenolic substances with
potent antioxidative and chemopreventive properties
[24]. Scapagnini et al. have previously shown that curcu-
min (1,7-bis [4-Hydroxy-3-methoxyphenyl]-1,6-heptadi-
ene-3,5-dione), a natural phenolic agent, extracted from
the rhizome of Curcuma Longa, strongly induced HO-1
expression and activity in rat astrocytes [25]. The Authors
have then extended their findings demonstrating curcu-
min ability to induce HO-1 in cultured hippocampal neu-
rons [26]. The results indicate that curcumin activates
HO-1 and phase II enzymes expression in astrocytes and
neurons, probably by activation of transcription factor
Nrf2, and this activation is able to effort a significant cyto-
protection in cultured neurons exposed to oxidative stress.
The involvement of curcumin in restoring cellular home-
ostasis and rebalancing redox equilibrium, suggests that it
might be a useful adjunct also in the treatment of neuro-
degenerative illnesses characterized by inflammation,
such as AD. This idea has been reinforced by epidemiolog-
ical studies showing that, in India where this spice is
widely used in daily diet, there is a reduced age-adjusted
prevalence of AD (in patients between 70 and 79 years of
age is 4.4-fold less than that of the United States) [27].
Consistent with its possible use in neurodegenerative dis-
eases, curcumin has been reported to decrease oxidative
damage and amyloid deposition in a transgenic mouse
model of Alzheimer's disease, and to reverse Aβ-inducedImmunity & Ageing 2008, 5:7 http://www.immunityageing.com/content/5/1/7
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cognitive deficits and neuropathology in rats [28,29].
Other plant-derived phenolic agents with analogous
chemical structures to curcumin have been demonstrated
to strongly activate HO-1 expression and to defend cells
against oxidative stress. In particular, Scapagnini et al.
have shown that ethyl ferulate, resveratrol (a phitoalexin
derived from grape) and caffeic acid phenethyl ester
(CAPE), are able to protect neurons via HO-1 induction
[30]. These and other studies identify a novel class of nat-
ural substances that could be used for therapeutic pur-
poses as potent inducers of HO-1 in the protection of
tissues against inflammatory and neurodegenerative con-
ditions. It needs to be emphasized that curcumin, and
other plant constituents eventually become part of the
human diet and can be consumed daily as herbal supple-
ments. Further in vitro and in vivo studies using curcu-
min-like molecules will give important information on
the feasibility of developing new pharmacological strate-
gies for maximizing heme oxygenase activity in targeted
tissues as an alternative to or in combination with HO-1
gene therapy.
However, curcumin studies are a growing area in AD
research [31] as well as in other pathological conditions.
Various preclinical cell culture and animal studies suggest
that curcumin has potential as an antiproliferative, anti-
invasive, and antiangiogenic agent; as a mediator of
chemoresistance and radioresistance; as a chemopreven-
tive agent; and as a therapeutic agent in wound healing,
diabetes, AD, Parkinson disease, cardiovascular disease,
pulmonary disease, and arthritis [32].
Conclusion
A major goal of ongoing research in AD is to improve early
detection by developing tools to move diagnosis back-
ward in disease temporal course, i.e. before the clinical
manifestation of the disease, where a treatment might
play a decisive role in preventing or significantly retarding
the manifestation of the disease [2,33]. On the whole,
data here reviewed strongly suggest that the measurement
of conformationally altered p53 in blood cells has a high
ability to discriminate AD cases from normal ageing, Par-
kinson's disease and other dementias. On the other hand,
available data on the involvement of curcumin in restor-
ing cellular homeostasis and rebalancing redox equilib-
rium, suggest that curcumin might be an useful adjunct in
the treatment of neurodegenerative illnesses characterized
by inflammation, such as AD.
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